Lack of ritonavir antifungal effect in vitro [2]

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 4, 1999, Pages 997-

  Diz, P ^a   Ocampo, A ^b   Iglesias, I ^b   Otero, I ^b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL XERAL CÍES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; RITONAVIR;

ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; DRUG SENSITIVITY; GROWTH INHIBITION; LETTER; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; THRUSH; VIRULENCE;

EID: 0344889212     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.4.997     Document Type: Letter

References (11)

1. Cassone, A., A. Adriani, E. Tacconelli, R. Cauda, and F. De Bernardis. 1998. HIV protease inhibitors have a direct anti-Candida effect by inhibition of Candida aspartyl proteinase abstr. 42358. Presented at the 12th World AIDS Conference, Geneva, Switzerland.
2. De Bernardis, F., P. Chiani, M. Ciccozzi, et al. 1996. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect. Immun. 64:466-471.
3. Greenspan, J. S. 1997. Sentinels and signposts. The epidemiology and significance of the oral manifestations of HIV disease. Oral Dis. 3(Suppl. 1):s13-s17.
4. Gruber, A., E. Lukasser-Vogl, M. B. Zepelin, M. P. Dierich, and R. Würzner. 1998. Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. J. Infect. Dis. 177:1057-1063.
5. Hoegl, L., M. Ollert, and H. C. Korting. 1996. The role of Candida albicans secreted aspartic proteinase in the development of candidoses. J. Mol. Med. 74:135-142.
6. Hood, S., A. Bonington, J. Evans, and D. Denning. 1998. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 14(4):447-448.
7. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved method M27-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
8. Odds, F. C. 1997. Personal opinion: can antifungal sensitivity tests predict clinical treatment outcomes? Rev. Iberoam. Micol. 14:83-84.
9. Senet, J. M. 1997. Risk factors and physiopathology of candidiasis. Rev. Iberoam. Micol. 14:6-13.
10. Valdez, H., B. M. Gripshover, R. A. Salata, and M. M. Lederman. 1998. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. AIDS 12(5):538.
11. Zingman, B. S. 1996. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N. Engl. J. Med. 334: 1674-1675.